Galapagos NV
Industriepark Mechelen Noord I, Zone L
Generaal De Wittelaan 11 A
Mechelen
B-2800
Tel: 32-15-34-29-00
Fax: 32-15-34-29-01
Website: http://www.galapagosgenomics.com/
538 articles with Galapagos NV
-
Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study
7/14/2021
Galapagos NV (Euronext & Nasdaq: GLPG)reports positive topline resultswith tyrosine kinase 2 (TYK2) inhibitor GLPG3667 in a Phase 1b studyin psoriasis patients.GLPG3667 was discovered by Galapagos.
-
Galapagos demonstrates early clinical activity with SIK2/3 inhibition in inflammation
7/14/2021
Galapagos NV(Euronext & Nasdaq: GLPG)reports topline results with GLPG3970 in three patientstudies.GLPG3970, the first product candidatefrom a broad portfolio of SIK inhibitor compounds, provides clinicaldatasupporting the role of SIK inhibition in inflammation.
-
In its 2Q2021 Clinical Report, BioSpace highlights drugs that were greenlit for clinical studies, faced clinical and regulatory hurdles and some who saw regulatory wins.
-
While the drug showed significant improvement in patients on a 200mg daily dose of filgotinib, it may not be promoted in the states any time soon.
-
Galapagos announces new data supporting rapid symptom improvement and sustained steroid-free remission with filgotinib in patients with Ulcerative Colitis
7/10/2021
Mechelen, Belgium; 10 July 2021, 11.10 CET; Galapagos NV announced new post-hoc analyses from the Phase 3 SELECTION program, supporting the activity and tolerability of filgotinib, a once-daily, oral JAK1 preferential inhibitor, under investigation for the treatment of patients with moderately to severely active ulcerative colitis.
-
Galapagos increases share capital through subscription right exercises
6/7/2021
Pursuant to the subscription right exercise program of Galapagos’ management board, members of the management board automatically are committed to exercise a minimum number of subscription rights, subject to certain conditions.
-
SELECTION study on filgotinib in ulcerative colitis published in The Lancet
6/4/2021
Galapagos NV announced that primary and secondary endpoint results from the phase 3 SELECTIONinduction and maintenance study were published in The Lancet00666-8).The study, sponsored by Gilead Sciences, Inc., was designed to assess the efficacy and safety of the once-daily, oral preferential JAK1 inhibitor, filgotinib, under investigation in patients with moderately to severely active ulcerative colitis.
-
Galapagos to present data on rheumatoid arthritis at the upcoming European League Against Rheumatism (EULAR) congress
5/27/2021
Galapagos NV (Euronext & Nasdaq: GLPG) today announced that 15 abstracts,including scientific updates, and data providing further understanding on the profile of filgotinib as a treatment for people with Rheumatoid Arthritis (RA), will be presented at the European League Against Rheumatism (EULAR) virtual congress 2021, 2-5 June.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Galapagos announces first patient enrolled in FILOSOPHY study to advance understanding of Jyseleca (filgotinib) effectiveness and safety in a real-world setting
5/18/2021
Study uses mobile device technology to support capture of patient-reported outcomes during early and ongoing use of study treatment amongst patients with rheumatoid arthritis
-
Galapagos NV will refocus its clinical pipeline and make some cost adjustments to save the company €150 million after disappointing studies assessing therapies for rheumatoid arthritis and idiopathic pulmonary fibrosis.
-
Galapagos refocuses pipeline and rightsizes operations
5/6/2021
Mechelen, Belgium; 06May 2021, 22.01 CET; regulated information – Galapagos NV announces its unaudited Q1results and operational highlights, which are further detailed in theQ12021report available on the Galapagos website, www.glpg.com.
-
Galapagos creates new subscription right plans
4/30/2021
Mechelen, Belgium;30 April 2021, 22.01 CET; regulated information –– Galapagos NV announced that its supervisory board created 2,736,250subscription rights under new subscription rightplans for the benefit of the personnelof the company and its subsidiaries.
-
Belgium-based Galapagos NV and Foster City, California-based Gilead Sciences halted the ISABELA Phase III clinical trial of ziritaxestat in idiopathic pulmonary fibrosis.
-
Selvita completes acquisition of Fidelta from Galapagos
1/4/2021
Galapagos NV and Selvita S.A. announced that the strategic transaction in which Selvita has acquired Fidelta from Galapagos has been completed.
-
A little more than one year after Gilead Sciences and Galapagos NV announced intentions to seek regulatory approval for Jyseleca (filgotinib) as a treatment for rheumatoid arthritis, the companies have pulled the plug on that goal.
-
European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Ulcerative Colitis
11/2/2020
Gilead Sciences, Inc. and Galapagos NV announced that the application for a new indication to the approved license for filgotinib 200 mg, an oral JAK1 preferential inhibitor, has been validated and is now under evaluation by the European Medicines Agency.
-
Clinical Catch-Up: October 12-16
10/19/2020
It was another busy week for both COVID-19-related clinical trial news as well as trial updates for other indications. Here’s a look. -
Back to the Drawing Board: Galapagos and Servier's Arthritis Knee Repair Drug Fails Phase II
10/16/2020
Galapagos NV and Servier reported that their ROCELLA Phase II clinical trial of GLPG1972/S201086 failed to meet its primary endpoint in osteoarthritis knee repair. -
Gilead and Galapagos Announce Positive European CHMP Opinion for Jyseleca® (Filgotinib) for the Treatment of Adults With Moderate to Severe Rheumatoid Arthritis
7/24/2020
Gilead and Galapagos Announce Positive European CHMP Opinion for Jyseleca ® (Filgotinib) for the Treatment of Adults With Moderate to Severe Rheumatoid Arthritis -- Clinical Development Program of Filgotinib Demonstrated Durable Efficacy Balanced with a Consistent Safety Profile in Rheumatoid Arthritis Through 52 Weeks -- FOSTER CITY, Calif., & MECHELEN, Belgium--( BUSINESS WIRE )-- Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronex